Skip to main content

Advertisement

SpringerLink
Log in

Functional Autoantibodies in Systemic Sclerosis Pathogenesis

  • Scleroderma (J Varga, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Circulating antinuclear autoantibodies contribute to the diagnosis of systemic sclerosis (SSc) and correlate with disease-specific organ manifestations. Recent findings show the induction of interstitial lung disease and obliterative vasculopathy by transfer of IgG from SSc patients in healthy mice indicating a contribution of antibodies to SSc pathogenesis. Several functional or agonistic autoantibodies have been described in SSc, thus putting autoimmunity into a new spotlight. Autoantibodies against the angiotensin II receptor type-1 and the endothelin1 receptor type-A are associated with severe disease and provide new insights into its pathogenesis. They link the hallmarks of SSc, vasculopathy, immune activation, and fibrosis. At present, the contribution of the specific antibodies to disease manifestations remains to be examined. However; functional autoantibodies could represent a significant piece in the puzzle of SSc pathogenesis and may open new gateways and opportunities for therapeutic intervention. This review focuses on the features of functional autoantibodies in SSc.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mierau R et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther. 2011;13:R172.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol. 1998;37:15–20.

    Article  CAS  PubMed  Google Scholar 

  3. Jacobsen S et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol. 1998;37:39–45.

    Article  CAS  PubMed  Google Scholar 

  4. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger Jr TA. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007;34:104–9.

    PubMed  Google Scholar 

  5. Hamaguchi Y et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol. 2008;158:487–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Denton CP et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis. 2012;71:718–21.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35–42.

    Article  CAS  PubMed  Google Scholar 

  8. Carvalho D, Savage CO, Black CM, Pearson JD. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest. 1996;97:111–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Sgonc R et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000;43:2550–62.

    Article  CAS  PubMed  Google Scholar 

  10. Ahmed SS, Tan FK, Arnett FC, Jin L, Geng YJ. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum. 2006;54:2250–62.

    Article  CAS  PubMed  Google Scholar 

  11. Worda M et al. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum. 2003;48:2605–14.

    Article  CAS  PubMed  Google Scholar 

  12. Wolf SI, Howat S, Abraham DJ, Pearson JD, Lawson C. Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades. Vasc Pharmacol. 2013;59:19–26.

    Article  CAS  Google Scholar 

  13. Chizzolini C et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum. 2002;46:1602–13.

    Article  CAS  PubMed  Google Scholar 

  14. Baroni SS et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667–76.

    Article  CAS  PubMed  Google Scholar 

  15. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Investig Dermatol. 1994;103:359–63.

    Article  CAS  PubMed  Google Scholar 

  16. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Investig Dermatol. 2003;120:542–7.

    Article  CAS  PubMed  Google Scholar 

  17. Nishijima C et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol. 2004;138:357–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Riemekasten G et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011;70:530–6.

    Article  CAS  PubMed  Google Scholar 

  19. Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, Witzenrath M, Kühl AA, Heidecke H, Ghofrani HA, Tiede H, Schermuly RT, Nickel N, Hoeper MM, Lukitsch I, Gollasch M, Kuebler WM, Bock S, Burmester GR, Dragun D, Riemekasten G. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med. 2014;190(7):808–17.

  20. Sambo P et al. Monocytes of patients with systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion. J Investig Dermatol. 1999;112:78–84.

    Article  CAS  PubMed  Google Scholar 

  21. Lindqvist KJ, Osterland CK. Human antibodies to vascular endothelium. Clin Exp Immunol. 1971;9:753–60.

    PubMed Central  CAS  PubMed  Google Scholar 

  22. Hebbar M et al. Assessment of anti-endothelial cell antibodies in systemic sclerosis and Sjogren’s syndrome. Ann Rheum Dis. 1997;56:230–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Renaudineau Y et al. Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol. 1999;6:156–60.

    PubMed Central  CAS  PubMed  Google Scholar 

  24. Ihn H et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol. 2000;119:203–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Salojin KV et al. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med. 1997;102:178–85.

    Article  CAS  PubMed  Google Scholar 

  26. Wusirika R et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol. 2003;120:596–606.

    Article  CAS  PubMed  Google Scholar 

  27. Renaudineau Y, Dugue C, Dueymes M, Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev. 2002;1:365–72.

    Article  CAS  PubMed  Google Scholar 

  28. Salih AM, Nixon NB, Dawes PT, Mattey DL. Soluble adhesion molecules and anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy. J Rheumatol. 1999;26:551–5.

    CAS  PubMed  Google Scholar 

  29. Belizna C, Duijvestijn A, Hamidou M, Tervaert JW. Antiendothelial cell antibodies in vasculitis and connective tissue disease. Ann Rheum Dis. 2006;65:1545–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Tamby MC et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax. 2005;60:765–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Servettaz A et al. Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). Clin Immunol. 2006;120:212–9.

    Article  CAS  PubMed  Google Scholar 

  32. Pignone A et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol. 1998;16:527–32.

    CAS  PubMed  Google Scholar 

  33. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol. 1998;25:462–6.

    CAS  PubMed  Google Scholar 

  34. Sgonc R et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996;98:785–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Tamby MC et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J. 2006;28:799–807.

    Article  CAS  PubMed  Google Scholar 

  36. Terrier B et al. Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis. 2010;69:428–33.

    Article  CAS  PubMed  Google Scholar 

  37. Balada E et al. Anti-PDGFR-alpha antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann Rheum Dis. 2008;67:1027–9.

    Article  CAS  PubMed  Google Scholar 

  38. Loizos N et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum. 2009;60:1145–51.

    Article  CAS  PubMed  Google Scholar 

  39. Dragun D, Distler JH, Riemekasten G, Distler O. Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum. 2009;60(4):907–11.

    Article  PubMed  Google Scholar 

  40. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol. 2010;37:11–25.

    Article  CAS  PubMed  Google Scholar 

  41. Lovell CR, Nicholls AC, Duance VC, Bailey AJ. Characterization of dermal collagen in systemic sclerosis. Br J Dermatol. 1979;100:359–69.

    Article  CAS  PubMed  Google Scholar 

  42. Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin N Am. 1996;22:647–74.

    Article  CAS  Google Scholar 

  43. Kill A et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther. 2014;16:R29.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Gunther J et al. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther. 2014;16:R65.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Cutolo M et al. The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann N Y Acad Sci. 2010;1193:36–42.

    Article  CAS  PubMed  Google Scholar 

  46. Pierdominici M et al. Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol Lett. 2010;132:79–85.

    Article  CAS  PubMed  Google Scholar 

  47. Colasanti T et al. Autoantibodies to estrogen receptor alpha interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2012;64:778–87.

    Article  CAS  PubMed  Google Scholar 

  48. Giovannetti A et al. Autoantibodies to estrogen receptor alpha in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression. PLoS One. 2013;8:e74332.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Sambo P et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001;44:2653–64.

    Article  CAS  PubMed  Google Scholar 

  50. Ogawa F et al. Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. Arch Dermatol Res. 2010;302:27–35.

    Article  CAS  PubMed  Google Scholar 

  51. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci. 2008;53:1163–74.

    Article  PubMed  Google Scholar 

  52. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin N Am. 1998;27:563–94.

    Article  CAS  Google Scholar 

  53. Kawaguchi Y et al. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann Rheum Dis. 2009;68:710–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Angela Kill and Gabriela Riemekasten declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Author information

Authors and Affiliations

  1. Department of Rheumatology and Clinical Immunology, University Hospital Charité, Luisenstraße 13, 10117, Berlin, Germany

    Angela Kill & Gabriela Riemekasten

  2. German Rheumatism Research Centre (DRFZ), A Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany

    Angela Kill & Gabriela Riemekasten

Authors
  1. Angela Kill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriela Riemekasten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriela Riemekasten.

Additional information

This article is part of the Topical Collection on Scleroderma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kill, A., Riemekasten, G. Functional Autoantibodies in Systemic Sclerosis Pathogenesis. Curr Rheumatol Rep 17, 34 (2015). https://doi.org/10.1007/s11926-015-0505-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-015-0505-4

Keywords

Search

Navigation